Abstract 488P
Background
Clinical investigations have great interest in understanding how ground-glass opacities (GGO) evolve into solid nodular lung adenocarcinoma (LUAD). However, there exists a dearth of research on ecosystem-level dynamics. Comprehensive insights into this phenomenon hinge on patient biopsies, which, when coupled with advanced single cell studies, hold the potential to unravel the intricacies of GGO progression and its transition into solid nodular LUAD.
Methods
We implemented a machine-learning framework to analyze scRNA-seq and WGS data derived from 55 patients stratified based on radiological patterns. In combination with in situ multiplex IF and HLA-immunopeptidome, we analysed the immune-ecosystem associated neoantigen presentation, followed by validation with HLA-tetramer CD8 T cell assay. Based on these methods, we consequently refined early-stage LUAD classification.
Results
We defined six lung immune multicellular ecotypes (LIMEs), in which two cancer cell state-associated LIMEs were implicated in distinct radiological patterns. These early stage malignant cells, through presenting GGO-associated neoantigens, were recognized by CXCL13+ CD8 T cells that formed an anti-tumoral LIME with other stromal cells. Solid nodular specific LIMEs, containing CTHRC1+ CAFs, SPP1+ TAMs and BANK1+ B cells, through inter-ecotype interactions, drove CD8 T cell exhaustion, leading to tumour progression.
Conclusions
This work offers an ecosystem-level portrayal of early-stage LUAD. It furnishes a resource for delving into the pre-malignant transformation of lung epithelium and its associated microenvironment. It outlines both intrinsic and extrinsic mechanisms that underpin the emergence of GGO and subsolid patterns. It imparts biological rationales as to select patients with early-stage LUAD might benefit from perioperative adjuvant therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
West China Hospital, Sichuan University, Chengdu, China.
Funding
National Science Fondation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract